DiaSorin SpA
MIL:DIA
Intrinsic Value
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics. [ Read More ]
The intrinsic value of one DIA stock under the Base Case scenario is 88.1 EUR. Compared to the current market price of 101.35 EUR, DiaSorin SpA is Overvalued by 13%.
Valuation Backtest
DiaSorin SpA
Run backtest to discover the historical profit from buying and selling DIA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
DiaSorin SpA
Current Assets | 982.7m |
Cash & Short-Term Investments | 403.4m |
Receivables | 228.7m |
Other Current Assets | 350.6m |
Non-Current Assets | 2.2B |
Long-Term Investments | 12.9m |
PP&E | 256.3m |
Intangibles | 1.9B |
Other Non-Current Assets | 34.6m |
Current Liabilities | 320.1m |
Accounts Payable | 100.7m |
Accrued Liabilities | 66.2m |
Other Current Liabilities | 153.2m |
Non-Current Liabilities | 1.4B |
Long-Term Debt | 1.1B |
Other Non-Current Liabilities | 269.7m |
Earnings Waterfall
DiaSorin SpA
Revenue
|
1.1B
EUR
|
Cost of Revenue
|
-407m
EUR
|
Gross Profit
|
741.2m
EUR
|
Operating Expenses
|
-503.3m
EUR
|
Operating Income
|
237.8m
EUR
|
Other Expenses
|
-78m
EUR
|
Net Income
|
159.8m
EUR
|
Free Cash Flow Analysis
DiaSorin SpA
DIA Profitability Score
Profitability Due Diligence
DiaSorin SpA's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
DiaSorin SpA's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
DIA Solvency Score
Solvency Due Diligence
DiaSorin SpA's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
DiaSorin SpA's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DIA Price Targets Summary
DiaSorin SpA
According to Wall Street analysts, the average 1-year price target for DIA is 98.47 EUR with a low forecast of 75.75 EUR and a high forecast of 115.5 EUR.
Shareholder Return
DIA Price
DiaSorin SpA
Average Annual Return | 12.25% |
Standard Deviation of Annual Returns | 29.7% |
Max Drawdown | -60% |
Market Capitalization | 5.4B EUR |
Shares Outstanding | 54 446 611 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,358 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Contact
IPO
Employees
Officers
The intrinsic value of one DIA stock under the Base Case scenario is 88.1 EUR.
Compared to the current market price of 101.35 EUR, DiaSorin SpA is Overvalued by 13%.